Personalized Cancer Treatment Platform using AI, IoT, and Blockchain
Legal Citation
Summary of the Inventive Concept
A comprehensive system integrating a growth hormone antagonist and anti-cancer composition with AI, IoT, and blockchain technologies for personalized cancer treatment planning, real-time monitoring, and secure data sharing.
Background and Problem Solved
The original patent disclosed a combination therapy for treating cancer using a growth hormone antagonist and anti-cancer composition. However, it lacked personalized treatment planning, real-time monitoring, and secure data sharing capabilities. The new inventive concept addresses these limitations by integrating AI, IoT, and blockchain technologies to provide a more effective and efficient cancer treatment platform.
Detailed Description of the Inventive Concept
The system comprises a growth hormone antagonist and an anti-cancer composition, which are integrated with an AI module for personalized cancer treatment planning. The AI module analyzes patient data, medical history, and genomic information to provide tailored treatment recommendations. The system also includes an IoT-enabled device for real-time monitoring of patient response, enabling healthcare providers to adjust treatment plans accordingly. Furthermore, a blockchain-based platform is used for securely storing and sharing medical records, ensuring secure access to treatment data for healthcare providers and researchers. Additionally, the growth hormone antagonist can be conjugated to a nanoparticle made of a novel, biocompatible material for enhanced targeted delivery.
Novelty and Inventive Step
The new claims introduce the integration of AI, IoT, and blockchain technologies with the growth hormone antagonist and anti-cancer composition, providing a novel and non-obvious solution for personalized cancer treatment. The inventive step lies in the synergistic combination of these distinct technologies to create a more effective and efficient cancer treatment platform.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include the use of different AI algorithms, IoT devices, or blockchain platforms. Additionally, the growth hormone antagonist could be replaced with other cancer treatment agents, or the nanoparticle material could be modified to enhance targeted delivery.
Potential Commercial Applications and Market
The personalized cancer treatment platform has significant commercial potential in the healthcare industry, particularly in the areas of cancer treatment, personalized medicine, and digital health. The platform could be marketed to healthcare providers, pharmaceutical companies, and research institutions, offering a competitive advantage in cancer treatment and research.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K38/27 |
| A | A61 | A61K45/06 |
| A | A61 | A61K47/10 |
| A | A61 | A61P35/00 |
| A | A61 | A61K2039/505 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Oncology, biotechnology, and medical treatment technologies, specifically focused on targeted cancer therapies involving growth hormone receptor antagonists and personalized medicine approaches
Person of Ordinary Skill (PHOSITA) Profile
A skilled practitioner with advanced degrees in biotechnology, oncology, or biomedical engineering, possessing expertise in molecular biology, cancer treatment strategies, and emerging medical technologies including AI and data integration platforms
Obviousness Rationale
A person of ordinary skill would recognize the natural progression of cancer treatment technologies from targeted molecular therapies to integrated personalized medicine platforms. The combination of growth hormone antagonist technologies with AI, IoT, and blockchain represents an incremental and predictable extension of existing cancer treatment methodologies. The technical elements disclosed in the PTD demonstrate a systematic approach to enhancing treatment personalization using known technological integration strategies.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,602 |
|---|---|
| Title | Growth hormone antagonist and anti-cancer composition combination therapy |